Proposed Changes to BenevolentAI’s Board Composition
BenevolentAI (or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that following extensive discussions with Mr.
Dr.
Subject to their appointment at the AGM, it is proposed that
The shareholders entitled to participate and vote at the 2024 AGM will be those who are shareholders on the record date of
Dr.
“The Board acknowledges that our dialogue with
“It has been a privilege to lead this excellent board and I would like to take this opportunity to extend our appreciation to Olivier, Susan and Marcello for their significant contributions to the Board since joining. The Company has benefitted significantly from their wise counsel and experience.”
Biographies of the Non-Executive Directors to be proposed at the AGM:
Mr.
A chartered accountant by background, Peter has over 30 years’ experience as an Executive Director, Non-Executive Director and Chairman in a wide range of life science companies, playing a significant role in their growth. He spent nine years as Chairman of
Peter is currently a Non-Executive Director at
Mr.
Kenneth is a prominent figure in the intersection of technology and bioscience and is known for his entrepreneurial spirit and innovative contributions to drug discovery. He is the founder of BenevolentAI and was the Company’s Chairman from its 2013 foundation until
Under Kenneth’s leadership BenevolentAI transitioned from a small group to a market leader by achieving early commercial success. This trajectory led to the honour of being named a 2018 Technology Pioneer by the
Before establishing BenevolentAI, he was the founder and CEO of
In addition to leading innovative companies, Kenneth has proactively served on several advisory boards for, amongst others, the
Kenneth has also dedicated efforts to philanthropy and was the Chairman of the Trustees for the Cure Parkinson’s Trust.
Mr.
Jeremy is Managing Partner of
Prior to launching P74, Jeremy was VP, Global Head of Digital BD&L, Partnerships & Innovation at Novartis, where he oversaw three teams: a pharma-tech and digital health venture fund, (operating as dRx Capital); a digital BD&L partnership and transactions team; and the Novartis Biome, an internal innovation community.
Prior to Novartis, he was Managing Director at
From 2007-2011, Jeremy was COO and VP Strategy & Corporate Development for North Plains Systems, where he led the company's growth and sale to
Mr.
Ian has over 40 years’ international experience in management and transactions within the life sciences sector. He has extensive Board experience in public and private companies and is currently Chairman of Bioventix plc, where he was appointed in 2004 and a Board Trustee of
He has been an Operating Partner at
From 2013 to 2021 Ian was CEO of
He previously held the position of Senior Vice President, Business Development at
Ian served on the Board of
PUBLIC DISCLOSURE OF INSIDE INFORMATION IN ACCORDANCE WITH ARTICLE 17(1) OF THE REGULATION (EU) NO 596/2014 ON MARKET ABUSE (MARKET ABUSE REGULATION)
About BenevolentAI
At BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery.
The Company’s business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, advancing in-house pipelines to inflection points, and commercialising a suite of knowledge exploration tools.
Headquartered in
Forward-looking Statements
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "should" and similar expressions. Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; economic outlook and industry trends; developments in BenevolentAI’s markets; the impact of regulatory initiatives; and/or the strength of BenevolentAI’s competitors. These forward-looking statements reflect, at the time made, BenevolentAI’s beliefs, intentions and current targets/aims. Forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The forward-looking statements in this release are based upon various assumptions based on, without limitation, management's examination of historical operating trends, data contained in BenevolentAI’s records, and third-party data. Although BenevolentAI believes these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond BenevolentAI’s control. Forward-looking statements are not guarantees of future performance, and such risks, uncertainties, contingencies and other important factors could cause the actual outcomes and the results of operations, financial condition and liquidity of BenevolentAI or the industry to differ materially from those results expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date of this release. No representation or warranty is made that any of these forward- looking statements or forecasts will come to pass or that any forecast result will be achieved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240414365731/en/
Enquiries:
Investors:
fleur.wood@benevolent.ai / investors@benevolent.ai
T: +44(0) 203 781 9360
FTI Consulting:
BenevolentAI@fticonsulting.com
T: +44 203 727 1000
Source: BenevolentAI